OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
Shaun Patterson, Mhairi Copland
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 2, pp. 19-32
Open Access | Times Cited: 12

Showing 12 citing articles:

Intricate relationship between cancer stemness, metastasis, and drug resistance
Tikam Chand Dakal, Ravi Bhushan, Caiming Xu, et al.
MedComm (2024) Vol. 5, Iss. 10
Open Access | Times Cited: 8

The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia
Rhiannon G. Panting, Rishi S. Kotecha, Laurence C. Cheung
Experimental Hematology (2024) Vol. 133, pp. 104212-104212
Open Access | Times Cited: 5

The dynamic interaction of pediatric ALL cells and MSCs: influencing leukemic cell survival and modulating MSC β-catenin expression
Tuba Özdemir Sancı, İlkay Pişkin, Yasin Köksal, et al.
Histochemistry and Cell Biology (2025) Vol. 163, Iss. 1
Open Access

Leukemic Stem Cells and Hematological Malignancies
Hee-Seon Choi, Byoung Soo Kim, Sik Yoon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6639-6639
Open Access | Times Cited: 2

High-throughput formulation of reproducible 3D cancer microenvironments for drug testing in myelogenous leukemia
Magdalena Rudzińska, Laura Turos-Korgul, Debjita Mukherjee, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions
Delphine Réa, Sofiane Fodil, Étienne Lengliné, et al.
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 3, pp. 104-110
Closed Access | Times Cited: 1

A Microchip For Exosome Isolation That Can Be Impregnated With Imatinib Simultaneously: An In Vitro Analysis
Амир Монфаредан, Fakher Rahim, Gholamreza Tavoosidana, et al.
Russian Open Medical Journal (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1

Designing a microchip for exosome isolation with the ability to simultaneously impregnate it with imatinib: an in vitro analysis
Амир Монфаредан, Фахер Рахим, Кудайберди Г. Кожобеков, et al.
Radioelectronics Nanosystems Information Technologies (2024) Vol. 16, Iss. 2, pp. 223-238
Open Access | Times Cited: 1

Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Esther Sathya Bama Benjamin, Elizabeth Vinod, Raveen Stephen Stallon Illangeswaran, et al.
Cellular Signalling (2024) Vol. 116, pp. 111067-111067
Closed Access

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia
Gulsum E. Pamuk, Lori A. Ehrlich
Cancers (2024) Vol. 16, Iss. 21, pp. 3615-3615
Open Access

The expanding CML treatment landscape: an introspective commentary
Jeffrey H. Lipton
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 1

Page 1

Scroll to top